Global Macular Degeneration Drug Pipeline Market Research Report 2023
This report aims to provide a comprehensive presentation of the global market for Macular Degeneration Drug Pipeline, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Macular Degeneration Drug Pipeline.
The Macular Degeneration Drug Pipeline market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Macular Degeneration Drug Pipeline market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Macular Degeneration Drug Pipeline companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Macular Degeneration Drug Pipeline companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The Macular Degeneration Drug Pipeline market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Macular Degeneration Drug Pipeline market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Macular Degeneration Drug Pipeline companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
- Amgen
- Roche
- Adverum Biotechnologies
- AsclepiX Therapeutics
- Bioeq AG
- Sinocelltech
- RemeGen
- Grifols, S.A.
- Kyowa Kirin
- EyePoint Pharmaceutical
- IVERIC Bio
- Kodiak Sciences
- Ribomic
- Lineage Cell Therapeutics
- Graybug Vision
- CHABiotech
- Shanghai Henlius Biotech
- Bio-Thera Solutions
- Alteogen
- Outlook Therapeutics
- Gene therapy
- Small molecules
- Stem cell therapy
- Gene therapies
- Hospital
- Research Institute
- Commercial
- Other
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Macular Degeneration Drug Pipeline companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Macular Degeneration Drug Pipeline Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Gene therapy
1.2.3 Small molecules
1.2.4 Stem cell therapy
1.2.5 Gene therapies
1.3 Market by Application
1.3.1 Global Macular Degeneration Drug Pipeline Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Research Institute
1.3.4 Commercial
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Macular Degeneration Drug Pipeline Market Perspective (2018-2029)
2.2 Macular Degeneration Drug Pipeline Growth Trends by Region
2.2.1 Global Macular Degeneration Drug Pipeline Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Macular Degeneration Drug Pipeline Historic Market Size by Region (2018-2023)
2.2.3 Macular Degeneration Drug Pipeline Forecasted Market Size by Region (2024-2029)
2.3 Macular Degeneration Drug Pipeline Market Dynamics
2.3.1 Macular Degeneration Drug Pipeline Industry Trends
2.3.2 Macular Degeneration Drug Pipeline Market Drivers
2.3.3 Macular Degeneration Drug Pipeline Market Challenges
2.3.4 Macular Degeneration Drug Pipeline Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Macular Degeneration Drug Pipeline Players by Revenue
3.1.1 Global Top Macular Degeneration Drug Pipeline Players by Revenue (2018-2023)
3.1.2 Global Macular Degeneration Drug Pipeline Revenue Market Share by Players (2018-2023)
3.2 Global Macular Degeneration Drug Pipeline Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Macular Degeneration Drug Pipeline Revenue
3.4 Global Macular Degeneration Drug Pipeline Market Concentration Ratio
3.4.1 Global Macular Degeneration Drug Pipeline Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Macular Degeneration Drug Pipeline Revenue in 2022
3.5 Macular Degeneration Drug Pipeline Key Players Head office and Area Served
3.6 Key Players Macular Degeneration Drug Pipeline Product Solution and Service
3.7 Date of Enter into Macular Degeneration Drug Pipeline Market
3.8 Mergers & Acquisitions, Expansion Plans
4 MACULAR DEGENERATION DRUG PIPELINE BREAKDOWN DATA BY TYPE
4.1 Global Macular Degeneration Drug Pipeline Historic Market Size by Type (2018-2023)
4.2 Global Macular Degeneration Drug Pipeline Forecasted Market Size by Type (2024-2029)
5 MACULAR DEGENERATION DRUG PIPELINE BREAKDOWN DATA BY APPLICATION
5.1 Global Macular Degeneration Drug Pipeline Historic Market Size by Application (2018-2023)
5.2 Global Macular Degeneration Drug Pipeline Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Macular Degeneration Drug Pipeline Market Size (2018-2029)
6.2 North America Macular Degeneration Drug Pipeline Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Macular Degeneration Drug Pipeline Market Size by Country (2018-2023)
6.4 North America Macular Degeneration Drug Pipeline Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 EUROPE
7.1 Europe Macular Degeneration Drug Pipeline Market Size (2018-2029)
7.2 Europe Macular Degeneration Drug Pipeline Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Macular Degeneration Drug Pipeline Market Size by Country (2018-2023)
7.4 Europe Macular Degeneration Drug Pipeline Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 ASIA-PACIFIC
8.1 Asia-Pacific Macular Degeneration Drug Pipeline Market Size (2018-2029)
8.2 Asia-Pacific Macular Degeneration Drug Pipeline Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Region (2018-2023)
8.4 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 LATIN AMERICA
9.1 Latin America Macular Degeneration Drug Pipeline Market Size (2018-2029)
9.2 Latin America Macular Degeneration Drug Pipeline Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Macular Degeneration Drug Pipeline Market Size by Country (2018-2023)
9.4 Latin America Macular Degeneration Drug Pipeline Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Macular Degeneration Drug Pipeline Market Size (2018-2029)
10.2 Middle East & Africa Macular Degeneration Drug Pipeline Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Country (2018-2023)
10.4 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 KEY PLAYERS PROFILES
11.1 Amgen
11.1.1 Amgen Company Detail
11.1.2 Amgen Business Overview
11.1.3 Amgen Macular Degeneration Drug Pipeline Introduction
11.1.4 Amgen Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.1.5 Amgen Recent Development
11.2 Roche
11.2.1 Roche Company Detail
11.2.2 Roche Business Overview
11.2.3 Roche Macular Degeneration Drug Pipeline Introduction
11.2.4 Roche Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.2.5 Roche Recent Development
11.3 Adverum Biotechnologies
11.3.1 Adverum Biotechnologies Company Detail
11.3.2 Adverum Biotechnologies Business Overview
11.3.3 Adverum Biotechnologies Macular Degeneration Drug Pipeline Introduction
11.3.4 Adverum Biotechnologies Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.3.5 Adverum Biotechnologies Recent Development
11.4 AsclepiX Therapeutics
11.4.1 AsclepiX Therapeutics Company Detail
11.4.2 AsclepiX Therapeutics Business Overview
11.4.3 AsclepiX Therapeutics Macular Degeneration Drug Pipeline Introduction
11.4.4 AsclepiX Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.4.5 AsclepiX Therapeutics Recent Development
11.5 Bioeq AG
11.5.1 Bioeq AG Company Detail
11.5.2 Bioeq AG Business Overview
11.5.3 Bioeq AG Macular Degeneration Drug Pipeline Introduction
11.5.4 Bioeq AG Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.5.5 Bioeq AG Recent Development
11.6 Sinocelltech
11.6.1 Sinocelltech Company Detail
11.6.2 Sinocelltech Business Overview
11.6.3 Sinocelltech Macular Degeneration Drug Pipeline Introduction
11.6.4 Sinocelltech Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.6.5 Sinocelltech Recent Development
11.7 RemeGen
11.7.1 RemeGen Company Detail
11.7.2 RemeGen Business Overview
11.7.3 RemeGen Macular Degeneration Drug Pipeline Introduction
11.7.4 RemeGen Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.7.5 RemeGen Recent Development
11.8 Grifols, S.A.
11.8.1 Grifols, S.A. Company Detail
11.8.2 Grifols, S.A. Business Overview
11.8.3 Grifols, S.A. Macular Degeneration Drug Pipeline Introduction
11.8.4 Grifols, S.A. Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.8.5 Grifols, S.A. Recent Development
11.9 Kyowa Kirin
11.9.1 Kyowa Kirin Company Detail
11.9.2 Kyowa Kirin Business Overview
11.9.3 Kyowa Kirin Macular Degeneration Drug Pipeline Introduction
11.9.4 Kyowa Kirin Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.9.5 Kyowa Kirin Recent Development
11.10 EyePoint Pharmaceutical
11.10.1 EyePoint Pharmaceutical Company Detail
11.10.2 EyePoint Pharmaceutical Business Overview
11.10.3 EyePoint Pharmaceutical Macular Degeneration Drug Pipeline Introduction
11.10.4 EyePoint Pharmaceutical Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.10.5 EyePoint Pharmaceutical Recent Development
11.11 IVERIC Bio
11.11.1 IVERIC Bio Company Detail
11.11.2 IVERIC Bio Business Overview
11.11.3 IVERIC Bio Macular Degeneration Drug Pipeline Introduction
11.11.4 IVERIC Bio Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.11.5 IVERIC Bio Recent Development
11.12 Kodiak Sciences
11.12.1 Kodiak Sciences Company Detail
11.12.2 Kodiak Sciences Business Overview
11.12.3 Kodiak Sciences Macular Degeneration Drug Pipeline Introduction
11.12.4 Kodiak Sciences Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.12.5 Kodiak Sciences Recent Development
11.13 Ribomic
11.13.1 Ribomic Company Detail
11.13.2 Ribomic Business Overview
11.13.3 Ribomic Macular Degeneration Drug Pipeline Introduction
11.13.4 Ribomic Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.13.5 Ribomic Recent Development
11.14 Lineage Cell Therapeutics
11.14.1 Lineage Cell Therapeutics Company Detail
11.14.2 Lineage Cell Therapeutics Business Overview
11.14.3 Lineage Cell Therapeutics Macular Degeneration Drug Pipeline Introduction
11.14.4 Lineage Cell Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.14.5 Lineage Cell Therapeutics Recent Development
11.15 Graybug Vision
11.15.1 Graybug Vision Company Detail
11.15.2 Graybug Vision Business Overview
11.15.3 Graybug Vision Macular Degeneration Drug Pipeline Introduction
11.15.4 Graybug Vision Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.15.5 Graybug Vision Recent Development
11.16 CHABiotech
11.16.1 CHABiotech Company Detail
11.16.2 CHABiotech Business Overview
11.16.3 CHABiotech Macular Degeneration Drug Pipeline Introduction
11.16.4 CHABiotech Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.16.5 CHABiotech Recent Development
11.17 Shanghai Henlius Biotech
11.17.1 Shanghai Henlius Biotech Company Detail
11.17.2 Shanghai Henlius Biotech Business Overview
11.17.3 Shanghai Henlius Biotech Macular Degeneration Drug Pipeline Introduction
11.17.4 Shanghai Henlius Biotech Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.17.5 Shanghai Henlius Biotech Recent Development
11.18 Bio-Thera Solutions
11.18.1 Bio-Thera Solutions Company Detail
11.18.2 Bio-Thera Solutions Business Overview
11.18.3 Bio-Thera Solutions Macular Degeneration Drug Pipeline Introduction
11.18.4 Bio-Thera Solutions Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.18.5 Bio-Thera Solutions Recent Development
11.19 Alteogen
11.19.1 Alteogen Company Detail
11.19.2 Alteogen Business Overview
11.19.3 Alteogen Macular Degeneration Drug Pipeline Introduction
11.19.4 Alteogen Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.19.5 Alteogen Recent Development
11.20 Outlook Therapeutics
11.20.1 Outlook Therapeutics Company Detail
11.20.2 Outlook Therapeutics Business Overview
11.20.3 Outlook Therapeutics Macular Degeneration Drug Pipeline Introduction
11.20.4 Outlook Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.20.5 Outlook Therapeutics Recent Development
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Macular Degeneration Drug Pipeline Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Gene therapy
1.2.3 Small molecules
1.2.4 Stem cell therapy
1.2.5 Gene therapies
1.3 Market by Application
1.3.1 Global Macular Degeneration Drug Pipeline Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Research Institute
1.3.4 Commercial
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Macular Degeneration Drug Pipeline Market Perspective (2018-2029)
2.2 Macular Degeneration Drug Pipeline Growth Trends by Region
2.2.1 Global Macular Degeneration Drug Pipeline Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Macular Degeneration Drug Pipeline Historic Market Size by Region (2018-2023)
2.2.3 Macular Degeneration Drug Pipeline Forecasted Market Size by Region (2024-2029)
2.3 Macular Degeneration Drug Pipeline Market Dynamics
2.3.1 Macular Degeneration Drug Pipeline Industry Trends
2.3.2 Macular Degeneration Drug Pipeline Market Drivers
2.3.3 Macular Degeneration Drug Pipeline Market Challenges
2.3.4 Macular Degeneration Drug Pipeline Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Macular Degeneration Drug Pipeline Players by Revenue
3.1.1 Global Top Macular Degeneration Drug Pipeline Players by Revenue (2018-2023)
3.1.2 Global Macular Degeneration Drug Pipeline Revenue Market Share by Players (2018-2023)
3.2 Global Macular Degeneration Drug Pipeline Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Macular Degeneration Drug Pipeline Revenue
3.4 Global Macular Degeneration Drug Pipeline Market Concentration Ratio
3.4.1 Global Macular Degeneration Drug Pipeline Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Macular Degeneration Drug Pipeline Revenue in 2022
3.5 Macular Degeneration Drug Pipeline Key Players Head office and Area Served
3.6 Key Players Macular Degeneration Drug Pipeline Product Solution and Service
3.7 Date of Enter into Macular Degeneration Drug Pipeline Market
3.8 Mergers & Acquisitions, Expansion Plans
4 MACULAR DEGENERATION DRUG PIPELINE BREAKDOWN DATA BY TYPE
4.1 Global Macular Degeneration Drug Pipeline Historic Market Size by Type (2018-2023)
4.2 Global Macular Degeneration Drug Pipeline Forecasted Market Size by Type (2024-2029)
5 MACULAR DEGENERATION DRUG PIPELINE BREAKDOWN DATA BY APPLICATION
5.1 Global Macular Degeneration Drug Pipeline Historic Market Size by Application (2018-2023)
5.2 Global Macular Degeneration Drug Pipeline Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Macular Degeneration Drug Pipeline Market Size (2018-2029)
6.2 North America Macular Degeneration Drug Pipeline Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Macular Degeneration Drug Pipeline Market Size by Country (2018-2023)
6.4 North America Macular Degeneration Drug Pipeline Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 EUROPE
7.1 Europe Macular Degeneration Drug Pipeline Market Size (2018-2029)
7.2 Europe Macular Degeneration Drug Pipeline Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Macular Degeneration Drug Pipeline Market Size by Country (2018-2023)
7.4 Europe Macular Degeneration Drug Pipeline Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 ASIA-PACIFIC
8.1 Asia-Pacific Macular Degeneration Drug Pipeline Market Size (2018-2029)
8.2 Asia-Pacific Macular Degeneration Drug Pipeline Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Region (2018-2023)
8.4 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 LATIN AMERICA
9.1 Latin America Macular Degeneration Drug Pipeline Market Size (2018-2029)
9.2 Latin America Macular Degeneration Drug Pipeline Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Macular Degeneration Drug Pipeline Market Size by Country (2018-2023)
9.4 Latin America Macular Degeneration Drug Pipeline Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Macular Degeneration Drug Pipeline Market Size (2018-2029)
10.2 Middle East & Africa Macular Degeneration Drug Pipeline Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Country (2018-2023)
10.4 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 KEY PLAYERS PROFILES
11.1 Amgen
11.1.1 Amgen Company Detail
11.1.2 Amgen Business Overview
11.1.3 Amgen Macular Degeneration Drug Pipeline Introduction
11.1.4 Amgen Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.1.5 Amgen Recent Development
11.2 Roche
11.2.1 Roche Company Detail
11.2.2 Roche Business Overview
11.2.3 Roche Macular Degeneration Drug Pipeline Introduction
11.2.4 Roche Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.2.5 Roche Recent Development
11.3 Adverum Biotechnologies
11.3.1 Adverum Biotechnologies Company Detail
11.3.2 Adverum Biotechnologies Business Overview
11.3.3 Adverum Biotechnologies Macular Degeneration Drug Pipeline Introduction
11.3.4 Adverum Biotechnologies Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.3.5 Adverum Biotechnologies Recent Development
11.4 AsclepiX Therapeutics
11.4.1 AsclepiX Therapeutics Company Detail
11.4.2 AsclepiX Therapeutics Business Overview
11.4.3 AsclepiX Therapeutics Macular Degeneration Drug Pipeline Introduction
11.4.4 AsclepiX Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.4.5 AsclepiX Therapeutics Recent Development
11.5 Bioeq AG
11.5.1 Bioeq AG Company Detail
11.5.2 Bioeq AG Business Overview
11.5.3 Bioeq AG Macular Degeneration Drug Pipeline Introduction
11.5.4 Bioeq AG Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.5.5 Bioeq AG Recent Development
11.6 Sinocelltech
11.6.1 Sinocelltech Company Detail
11.6.2 Sinocelltech Business Overview
11.6.3 Sinocelltech Macular Degeneration Drug Pipeline Introduction
11.6.4 Sinocelltech Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.6.5 Sinocelltech Recent Development
11.7 RemeGen
11.7.1 RemeGen Company Detail
11.7.2 RemeGen Business Overview
11.7.3 RemeGen Macular Degeneration Drug Pipeline Introduction
11.7.4 RemeGen Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.7.5 RemeGen Recent Development
11.8 Grifols, S.A.
11.8.1 Grifols, S.A. Company Detail
11.8.2 Grifols, S.A. Business Overview
11.8.3 Grifols, S.A. Macular Degeneration Drug Pipeline Introduction
11.8.4 Grifols, S.A. Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.8.5 Grifols, S.A. Recent Development
11.9 Kyowa Kirin
11.9.1 Kyowa Kirin Company Detail
11.9.2 Kyowa Kirin Business Overview
11.9.3 Kyowa Kirin Macular Degeneration Drug Pipeline Introduction
11.9.4 Kyowa Kirin Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.9.5 Kyowa Kirin Recent Development
11.10 EyePoint Pharmaceutical
11.10.1 EyePoint Pharmaceutical Company Detail
11.10.2 EyePoint Pharmaceutical Business Overview
11.10.3 EyePoint Pharmaceutical Macular Degeneration Drug Pipeline Introduction
11.10.4 EyePoint Pharmaceutical Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.10.5 EyePoint Pharmaceutical Recent Development
11.11 IVERIC Bio
11.11.1 IVERIC Bio Company Detail
11.11.2 IVERIC Bio Business Overview
11.11.3 IVERIC Bio Macular Degeneration Drug Pipeline Introduction
11.11.4 IVERIC Bio Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.11.5 IVERIC Bio Recent Development
11.12 Kodiak Sciences
11.12.1 Kodiak Sciences Company Detail
11.12.2 Kodiak Sciences Business Overview
11.12.3 Kodiak Sciences Macular Degeneration Drug Pipeline Introduction
11.12.4 Kodiak Sciences Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.12.5 Kodiak Sciences Recent Development
11.13 Ribomic
11.13.1 Ribomic Company Detail
11.13.2 Ribomic Business Overview
11.13.3 Ribomic Macular Degeneration Drug Pipeline Introduction
11.13.4 Ribomic Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.13.5 Ribomic Recent Development
11.14 Lineage Cell Therapeutics
11.14.1 Lineage Cell Therapeutics Company Detail
11.14.2 Lineage Cell Therapeutics Business Overview
11.14.3 Lineage Cell Therapeutics Macular Degeneration Drug Pipeline Introduction
11.14.4 Lineage Cell Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.14.5 Lineage Cell Therapeutics Recent Development
11.15 Graybug Vision
11.15.1 Graybug Vision Company Detail
11.15.2 Graybug Vision Business Overview
11.15.3 Graybug Vision Macular Degeneration Drug Pipeline Introduction
11.15.4 Graybug Vision Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.15.5 Graybug Vision Recent Development
11.16 CHABiotech
11.16.1 CHABiotech Company Detail
11.16.2 CHABiotech Business Overview
11.16.3 CHABiotech Macular Degeneration Drug Pipeline Introduction
11.16.4 CHABiotech Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.16.5 CHABiotech Recent Development
11.17 Shanghai Henlius Biotech
11.17.1 Shanghai Henlius Biotech Company Detail
11.17.2 Shanghai Henlius Biotech Business Overview
11.17.3 Shanghai Henlius Biotech Macular Degeneration Drug Pipeline Introduction
11.17.4 Shanghai Henlius Biotech Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.17.5 Shanghai Henlius Biotech Recent Development
11.18 Bio-Thera Solutions
11.18.1 Bio-Thera Solutions Company Detail
11.18.2 Bio-Thera Solutions Business Overview
11.18.3 Bio-Thera Solutions Macular Degeneration Drug Pipeline Introduction
11.18.4 Bio-Thera Solutions Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.18.5 Bio-Thera Solutions Recent Development
11.19 Alteogen
11.19.1 Alteogen Company Detail
11.19.2 Alteogen Business Overview
11.19.3 Alteogen Macular Degeneration Drug Pipeline Introduction
11.19.4 Alteogen Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.19.5 Alteogen Recent Development
11.20 Outlook Therapeutics
11.20.1 Outlook Therapeutics Company Detail
11.20.2 Outlook Therapeutics Business Overview
11.20.3 Outlook Therapeutics Macular Degeneration Drug Pipeline Introduction
11.20.4 Outlook Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2018-2023)
11.20.5 Outlook Therapeutics Recent Development
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
LIST OF TABLES
Table 1. Global Macular Degeneration Drug Pipeline Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Gene therapy
Table 3. Key Players of Small molecules
Table 4. Key Players of Stem cell therapy
Table 5. Key Players of Gene therapies
Table 6. Global Macular Degeneration Drug Pipeline Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global Macular Degeneration Drug Pipeline Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Macular Degeneration Drug Pipeline Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Macular Degeneration Drug Pipeline Market Share by Region (2018-2023)
Table 10. Global Macular Degeneration Drug Pipeline Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 11. Global Macular Degeneration Drug Pipeline Market Share by Region (2024-2029)
Table 12. Macular Degeneration Drug Pipeline Market Trends
Table 13. Macular Degeneration Drug Pipeline Market Drivers
Table 14. Macular Degeneration Drug Pipeline Market Challenges
Table 15. Macular Degeneration Drug Pipeline Market Restraints
Table 16. Global Macular Degeneration Drug Pipeline Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Macular Degeneration Drug Pipeline Market Share by Players (2018-2023)
Table 18. Global Top Macular Degeneration Drug Pipeline Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Macular Degeneration Drug Pipeline as of 2022)
Table 19. Ranking of Global Top Macular Degeneration Drug Pipeline Companies by Revenue (US$ Million) in 2022
Table 20. Global 5 Largest Players Market Share by Macular Degeneration Drug Pipeline Revenue (CR5 and HHI) & (2018-2023)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Macular Degeneration Drug Pipeline Product Solution and Service
Table 23. Date of Enter into Macular Degeneration Drug Pipeline Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Macular Degeneration Drug Pipeline Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Macular Degeneration Drug Pipeline Revenue Market Share by Type (2018-2023)
Table 27. Global Macular Degeneration Drug Pipeline Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 28. Global Macular Degeneration Drug Pipeline Revenue Market Share by Type (2024-2029)
Table 29. Global Macular Degeneration Drug Pipeline Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Macular Degeneration Drug Pipeline Revenue Market Share by Application (2018-2023)
Table 31. Global Macular Degeneration Drug Pipeline Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 32. Global Macular Degeneration Drug Pipeline Revenue Market Share by Application (2024-2029)
Table 33. North America Macular Degeneration Drug Pipeline Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 34. North America Macular Degeneration Drug Pipeline Market Size by Country (2018-2023) & (US$ Million)
Table 35. North America Macular Degeneration Drug Pipeline Market Size by Country (2024-2029) & (US$ Million)
Table 36. Europe Macular Degeneration Drug Pipeline Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 37. Europe Macular Degeneration Drug Pipeline Market Size by Country (2018-2023) & (US$ Million)
Table 38. Europe Macular Degeneration Drug Pipeline Market Size by Country (2024-2029) & (US$ Million)
Table 39. Asia-Pacific Macular Degeneration Drug Pipeline Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 40. Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Region (2018-2023) & (US$ Million)
Table 41. Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Region (2024-2029) & (US$ Million)
Table 42. Latin America Macular Degeneration Drug Pipeline Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 43. Latin America Macular Degeneration Drug Pipeline Market Size by Country (2018-2023) & (US$ Million)
Table 44. Latin America Macular Degeneration Drug Pipeline Market Size by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Macular Degeneration Drug Pipeline Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 46. Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Country (2018-2023) & (US$ Million)
Table 47. Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Country (2024-2029) & (US$ Million)
Table 48. Amgen Company Detail
Table 49. Amgen Business Overview
Table 50. Amgen Macular Degeneration Drug Pipeline Product
Table 51. Amgen Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 52. Amgen Recent Development
Table 53. Roche Company Detail
Table 54. Roche Business Overview
Table 55. Roche Macular Degeneration Drug Pipeline Product
Table 56. Roche Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 57. Roche Recent Development
Table 58. Adverum Biotechnologies Company Detail
Table 59. Adverum Biotechnologies Business Overview
Table 60. Adverum Biotechnologies Macular Degeneration Drug Pipeline Product
Table 61. Adverum Biotechnologies Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 62. Adverum Biotechnologies Recent Development
Table 63. AsclepiX Therapeutics Company Detail
Table 64. AsclepiX Therapeutics Business Overview
Table 65. AsclepiX Therapeutics Macular Degeneration Drug Pipeline Product
Table 66. AsclepiX Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 67. AsclepiX Therapeutics Recent Development
Table 68. Bioeq AG Company Detail
Table 69. Bioeq AG Business Overview
Table 70. Bioeq AG Macular Degeneration Drug Pipeline Product
Table 71. Bioeq AG Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 72. Bioeq AG Recent Development
Table 73. Sinocelltech Company Detail
Table 74. Sinocelltech Business Overview
Table 75. Sinocelltech Macular Degeneration Drug Pipeline Product
Table 76. Sinocelltech Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 77. Sinocelltech Recent Development
Table 78. RemeGen Company Detail
Table 79. RemeGen Business Overview
Table 80. RemeGen Macular Degeneration Drug Pipeline Product
Table 81. RemeGen Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 82. RemeGen Recent Development
Table 83. Grifols, S.A. Company Detail
Table 84. Grifols, S.A. Business Overview
Table 85. Grifols, S.A. Macular Degeneration Drug Pipeline Product
Table 86. Grifols, S.A. Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 87. Grifols, S.A. Recent Development
Table 88. Kyowa Kirin Company Detail
Table 89. Kyowa Kirin Business Overview
Table 90. Kyowa Kirin Macular Degeneration Drug Pipeline Product
Table 91. Kyowa Kirin Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 92. Kyowa Kirin Recent Development
Table 93. EyePoint Pharmaceutical Company Detail
Table 94. EyePoint Pharmaceutical Business Overview
Table 95. EyePoint Pharmaceutical Macular Degeneration Drug Pipeline Product
Table 96. EyePoint Pharmaceutical Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 97. EyePoint Pharmaceutical Recent Development
Table 98. IVERIC Bio Company Detail
Table 99. IVERIC Bio Business Overview
Table 100. IVERIC Bio Macular Degeneration Drug Pipeline Product
Table 101. IVERIC Bio Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 102. IVERIC Bio Recent Development
Table 103. Kodiak Sciences Company Detail
Table 104. Kodiak Sciences Business Overview
Table 105. Kodiak Sciences Macular Degeneration Drug Pipeline Product
Table 106. Kodiak Sciences Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 107. Kodiak Sciences Recent Development
Table 108. Ribomic Company Detail
Table 109. Ribomic Business Overview
Table 110. Ribomic Macular Degeneration Drug Pipeline Product
Table 111. Ribomic Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 112. Ribomic Recent Development
Table 113. Lineage Cell Therapeutics Company Detail
Table 114. Lineage Cell Therapeutics Business Overview
Table 115. Lineage Cell Therapeutics Macular Degeneration Drug Pipeline Product
Table 116. Lineage Cell Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 117. Lineage Cell Therapeutics Recent Development
Table 118. Graybug Vision Company Detail
Table 119. Graybug Vision Business Overview
Table 120. Graybug Vision Macular Degeneration Drug Pipeline Product
Table 121. Graybug Vision Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 122. Graybug Vision Recent Development
Table 123. CHABiotech Company Detail
Table 124. CHABiotech Business Overview
Table 125. CHABiotech Macular Degeneration Drug Pipeline Product
Table 126. CHABiotech Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 127. CHABiotech Recent Development
Table 128. Shanghai Henlius Biotech Company Detail
Table 129. Shanghai Henlius Biotech Business Overview
Table 130. Shanghai Henlius Biotech Macular Degeneration Drug Pipeline Product
Table 131. Shanghai Henlius Biotech Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 132. Shanghai Henlius Biotech Recent Development
Table 133. Bio-Thera Solutions Company Detail
Table 134. Bio-Thera Solutions Business Overview
Table 135. Bio-Thera Solutions Macular Degeneration Drug Pipeline Product
Table 136. Bio-Thera Solutions Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 137. Bio-Thera Solutions Recent Development
Table 138. Alteogen Company Detail
Table 139. Alteogen Business Overview
Table 140. Alteogen Macular Degeneration Drug Pipeline Product
Table 141. Alteogen Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 142. Alteogen Recent Development
Table 143. Outlook Therapeutics Company Detail
Table 144. Outlook Therapeutics Business Overview
Table 145. Outlook Therapeutics Macular Degeneration Drug Pipeline Product
Table 146. Outlook Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 147. Outlook Therapeutics Recent Development
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
Table 1. Global Macular Degeneration Drug Pipeline Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Gene therapy
Table 3. Key Players of Small molecules
Table 4. Key Players of Stem cell therapy
Table 5. Key Players of Gene therapies
Table 6. Global Macular Degeneration Drug Pipeline Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global Macular Degeneration Drug Pipeline Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Macular Degeneration Drug Pipeline Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Macular Degeneration Drug Pipeline Market Share by Region (2018-2023)
Table 10. Global Macular Degeneration Drug Pipeline Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 11. Global Macular Degeneration Drug Pipeline Market Share by Region (2024-2029)
Table 12. Macular Degeneration Drug Pipeline Market Trends
Table 13. Macular Degeneration Drug Pipeline Market Drivers
Table 14. Macular Degeneration Drug Pipeline Market Challenges
Table 15. Macular Degeneration Drug Pipeline Market Restraints
Table 16. Global Macular Degeneration Drug Pipeline Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Macular Degeneration Drug Pipeline Market Share by Players (2018-2023)
Table 18. Global Top Macular Degeneration Drug Pipeline Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Macular Degeneration Drug Pipeline as of 2022)
Table 19. Ranking of Global Top Macular Degeneration Drug Pipeline Companies by Revenue (US$ Million) in 2022
Table 20. Global 5 Largest Players Market Share by Macular Degeneration Drug Pipeline Revenue (CR5 and HHI) & (2018-2023)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Macular Degeneration Drug Pipeline Product Solution and Service
Table 23. Date of Enter into Macular Degeneration Drug Pipeline Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Macular Degeneration Drug Pipeline Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Macular Degeneration Drug Pipeline Revenue Market Share by Type (2018-2023)
Table 27. Global Macular Degeneration Drug Pipeline Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 28. Global Macular Degeneration Drug Pipeline Revenue Market Share by Type (2024-2029)
Table 29. Global Macular Degeneration Drug Pipeline Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Macular Degeneration Drug Pipeline Revenue Market Share by Application (2018-2023)
Table 31. Global Macular Degeneration Drug Pipeline Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 32. Global Macular Degeneration Drug Pipeline Revenue Market Share by Application (2024-2029)
Table 33. North America Macular Degeneration Drug Pipeline Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 34. North America Macular Degeneration Drug Pipeline Market Size by Country (2018-2023) & (US$ Million)
Table 35. North America Macular Degeneration Drug Pipeline Market Size by Country (2024-2029) & (US$ Million)
Table 36. Europe Macular Degeneration Drug Pipeline Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 37. Europe Macular Degeneration Drug Pipeline Market Size by Country (2018-2023) & (US$ Million)
Table 38. Europe Macular Degeneration Drug Pipeline Market Size by Country (2024-2029) & (US$ Million)
Table 39. Asia-Pacific Macular Degeneration Drug Pipeline Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 40. Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Region (2018-2023) & (US$ Million)
Table 41. Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Region (2024-2029) & (US$ Million)
Table 42. Latin America Macular Degeneration Drug Pipeline Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 43. Latin America Macular Degeneration Drug Pipeline Market Size by Country (2018-2023) & (US$ Million)
Table 44. Latin America Macular Degeneration Drug Pipeline Market Size by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Macular Degeneration Drug Pipeline Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 46. Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Country (2018-2023) & (US$ Million)
Table 47. Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Country (2024-2029) & (US$ Million)
Table 48. Amgen Company Detail
Table 49. Amgen Business Overview
Table 50. Amgen Macular Degeneration Drug Pipeline Product
Table 51. Amgen Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 52. Amgen Recent Development
Table 53. Roche Company Detail
Table 54. Roche Business Overview
Table 55. Roche Macular Degeneration Drug Pipeline Product
Table 56. Roche Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 57. Roche Recent Development
Table 58. Adverum Biotechnologies Company Detail
Table 59. Adverum Biotechnologies Business Overview
Table 60. Adverum Biotechnologies Macular Degeneration Drug Pipeline Product
Table 61. Adverum Biotechnologies Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 62. Adverum Biotechnologies Recent Development
Table 63. AsclepiX Therapeutics Company Detail
Table 64. AsclepiX Therapeutics Business Overview
Table 65. AsclepiX Therapeutics Macular Degeneration Drug Pipeline Product
Table 66. AsclepiX Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 67. AsclepiX Therapeutics Recent Development
Table 68. Bioeq AG Company Detail
Table 69. Bioeq AG Business Overview
Table 70. Bioeq AG Macular Degeneration Drug Pipeline Product
Table 71. Bioeq AG Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 72. Bioeq AG Recent Development
Table 73. Sinocelltech Company Detail
Table 74. Sinocelltech Business Overview
Table 75. Sinocelltech Macular Degeneration Drug Pipeline Product
Table 76. Sinocelltech Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 77. Sinocelltech Recent Development
Table 78. RemeGen Company Detail
Table 79. RemeGen Business Overview
Table 80. RemeGen Macular Degeneration Drug Pipeline Product
Table 81. RemeGen Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 82. RemeGen Recent Development
Table 83. Grifols, S.A. Company Detail
Table 84. Grifols, S.A. Business Overview
Table 85. Grifols, S.A. Macular Degeneration Drug Pipeline Product
Table 86. Grifols, S.A. Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 87. Grifols, S.A. Recent Development
Table 88. Kyowa Kirin Company Detail
Table 89. Kyowa Kirin Business Overview
Table 90. Kyowa Kirin Macular Degeneration Drug Pipeline Product
Table 91. Kyowa Kirin Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 92. Kyowa Kirin Recent Development
Table 93. EyePoint Pharmaceutical Company Detail
Table 94. EyePoint Pharmaceutical Business Overview
Table 95. EyePoint Pharmaceutical Macular Degeneration Drug Pipeline Product
Table 96. EyePoint Pharmaceutical Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 97. EyePoint Pharmaceutical Recent Development
Table 98. IVERIC Bio Company Detail
Table 99. IVERIC Bio Business Overview
Table 100. IVERIC Bio Macular Degeneration Drug Pipeline Product
Table 101. IVERIC Bio Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 102. IVERIC Bio Recent Development
Table 103. Kodiak Sciences Company Detail
Table 104. Kodiak Sciences Business Overview
Table 105. Kodiak Sciences Macular Degeneration Drug Pipeline Product
Table 106. Kodiak Sciences Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 107. Kodiak Sciences Recent Development
Table 108. Ribomic Company Detail
Table 109. Ribomic Business Overview
Table 110. Ribomic Macular Degeneration Drug Pipeline Product
Table 111. Ribomic Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 112. Ribomic Recent Development
Table 113. Lineage Cell Therapeutics Company Detail
Table 114. Lineage Cell Therapeutics Business Overview
Table 115. Lineage Cell Therapeutics Macular Degeneration Drug Pipeline Product
Table 116. Lineage Cell Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 117. Lineage Cell Therapeutics Recent Development
Table 118. Graybug Vision Company Detail
Table 119. Graybug Vision Business Overview
Table 120. Graybug Vision Macular Degeneration Drug Pipeline Product
Table 121. Graybug Vision Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 122. Graybug Vision Recent Development
Table 123. CHABiotech Company Detail
Table 124. CHABiotech Business Overview
Table 125. CHABiotech Macular Degeneration Drug Pipeline Product
Table 126. CHABiotech Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 127. CHABiotech Recent Development
Table 128. Shanghai Henlius Biotech Company Detail
Table 129. Shanghai Henlius Biotech Business Overview
Table 130. Shanghai Henlius Biotech Macular Degeneration Drug Pipeline Product
Table 131. Shanghai Henlius Biotech Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 132. Shanghai Henlius Biotech Recent Development
Table 133. Bio-Thera Solutions Company Detail
Table 134. Bio-Thera Solutions Business Overview
Table 135. Bio-Thera Solutions Macular Degeneration Drug Pipeline Product
Table 136. Bio-Thera Solutions Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 137. Bio-Thera Solutions Recent Development
Table 138. Alteogen Company Detail
Table 139. Alteogen Business Overview
Table 140. Alteogen Macular Degeneration Drug Pipeline Product
Table 141. Alteogen Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 142. Alteogen Recent Development
Table 143. Outlook Therapeutics Company Detail
Table 144. Outlook Therapeutics Business Overview
Table 145. Outlook Therapeutics Macular Degeneration Drug Pipeline Product
Table 146. Outlook Therapeutics Revenue in Macular Degeneration Drug Pipeline Business (2018-2023) & (US$ Million)
Table 147. Outlook Therapeutics Recent Development
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Macular Degeneration Drug Pipeline Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Macular Degeneration Drug Pipeline Market Share by Type: 2022 VS 2029
Figure 3. Gene therapy Features
Figure 4. Small molecules Features
Figure 5. Stem cell therapy Features
Figure 6. Gene therapies Features
Figure 7. Global Macular Degeneration Drug Pipeline Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 8. Global Macular Degeneration Drug Pipeline Market Share by Application: 2022 VS 2029
Figure 9. Hospital Case Studies
Figure 10. Research Institute Case Studies
Figure 11. Commercial Case Studies
Figure 12. Other Case Studies
Figure 13. Macular Degeneration Drug Pipeline Report Years Considered
Figure 14. Global Macular Degeneration Drug Pipeline Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 15. Global Macular Degeneration Drug Pipeline Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Macular Degeneration Drug Pipeline Market Share by Region: 2022 VS 2029
Figure 17. Global Macular Degeneration Drug Pipeline Market Share by Players in 2022
Figure 18. Global Top Macular Degeneration Drug Pipeline Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Macular Degeneration Drug Pipeline as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Macular Degeneration Drug Pipeline Revenue in 2022
Figure 20. North America Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. North America Macular Degeneration Drug Pipeline Market Share by Country (2018-2029)
Figure 22. United States Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Canada Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Europe Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe Macular Degeneration Drug Pipeline Market Share by Country (2018-2029)
Figure 26. Germany Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. France Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. U.K. Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Italy Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Russia Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Nordic Countries Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Asia-Pacific Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Asia-Pacific Macular Degeneration Drug Pipeline Market Share by Region (2018-2029)
Figure 34. China Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Japan Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. South Korea Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Southeast Asia Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. India Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Australia Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Latin America Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Latin America Macular Degeneration Drug Pipeline Market Share by Country (2018-2029)
Figure 42. Mexico Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Brazil Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Middle East & Africa Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Middle East & Africa Macular Degeneration Drug Pipeline Market Share by Country (2018-2029)
Figure 46. Turkey Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Saudi Arabia Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Amgen Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 49. Roche Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 50. Adverum Biotechnologies Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 51. AsclepiX Therapeutics Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 52. Bioeq AG Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 53. Sinocelltech Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 54. RemeGen Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 55. Grifols, S.A. Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 56. Kyowa Kirin Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 57. EyePoint Pharmaceutical Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 58. IVERIC Bio Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 59. Kodiak Sciences Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 60. Ribomic Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 61. Lineage Cell Therapeutics Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 62. Graybug Vision Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 63. CHABiotech Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 64. Shanghai Henlius Biotech Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 65. Bio-Thera Solutions Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 66. Alteogen Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 67. Outlook Therapeutics Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
Figure 1. Global Macular Degeneration Drug Pipeline Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Macular Degeneration Drug Pipeline Market Share by Type: 2022 VS 2029
Figure 3. Gene therapy Features
Figure 4. Small molecules Features
Figure 5. Stem cell therapy Features
Figure 6. Gene therapies Features
Figure 7. Global Macular Degeneration Drug Pipeline Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 8. Global Macular Degeneration Drug Pipeline Market Share by Application: 2022 VS 2029
Figure 9. Hospital Case Studies
Figure 10. Research Institute Case Studies
Figure 11. Commercial Case Studies
Figure 12. Other Case Studies
Figure 13. Macular Degeneration Drug Pipeline Report Years Considered
Figure 14. Global Macular Degeneration Drug Pipeline Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 15. Global Macular Degeneration Drug Pipeline Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Macular Degeneration Drug Pipeline Market Share by Region: 2022 VS 2029
Figure 17. Global Macular Degeneration Drug Pipeline Market Share by Players in 2022
Figure 18. Global Top Macular Degeneration Drug Pipeline Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Macular Degeneration Drug Pipeline as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Macular Degeneration Drug Pipeline Revenue in 2022
Figure 20. North America Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. North America Macular Degeneration Drug Pipeline Market Share by Country (2018-2029)
Figure 22. United States Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Canada Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Europe Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe Macular Degeneration Drug Pipeline Market Share by Country (2018-2029)
Figure 26. Germany Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. France Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. U.K. Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Italy Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Russia Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Nordic Countries Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Asia-Pacific Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Asia-Pacific Macular Degeneration Drug Pipeline Market Share by Region (2018-2029)
Figure 34. China Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Japan Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. South Korea Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Southeast Asia Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. India Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Australia Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Latin America Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Latin America Macular Degeneration Drug Pipeline Market Share by Country (2018-2029)
Figure 42. Mexico Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Brazil Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Middle East & Africa Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Middle East & Africa Macular Degeneration Drug Pipeline Market Share by Country (2018-2029)
Figure 46. Turkey Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Saudi Arabia Macular Degeneration Drug Pipeline Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Amgen Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 49. Roche Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 50. Adverum Biotechnologies Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 51. AsclepiX Therapeutics Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 52. Bioeq AG Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 53. Sinocelltech Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 54. RemeGen Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 55. Grifols, S.A. Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 56. Kyowa Kirin Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 57. EyePoint Pharmaceutical Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 58. IVERIC Bio Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 59. Kodiak Sciences Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 60. Ribomic Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 61. Lineage Cell Therapeutics Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 62. Graybug Vision Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 63. CHABiotech Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 64. Shanghai Henlius Biotech Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 65. Bio-Thera Solutions Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 66. Alteogen Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 67. Outlook Therapeutics Revenue Growth Rate in Macular Degeneration Drug Pipeline Business (2018-2023)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
